


Breaking Down Barriers to STI Testing & Treatment

**osom<sup>®</sup>**

TRICHOMONAS RAPID TEST



**248**  
MILLION CASES OF  
**TRICHOMONAS**

**101**  
MILLION CASES OF  
**CHLAMYDIA**

**88**  
MILLION CASES OF  
**GONORRHEA**

**11**  
MILLION CASES OF  
**SYPHILIS**

**448** MILLION NEW CURABLE **STIs** EACH YEAR<sup>1</sup>

# Trichomoniasis:

## Under diagnosed and under treated?

*TRICHOMONAS VAGINALIS* is estimated to be the most common, curable, non-viral sexually transmitted infection.<sup>2</sup> It is a motile parasite, approximately the size of a white blood cell, and is estimated to cause 20% of vaginitis complaints. Historically thought of as a nuisance infection, it can have serious health implications and has been largely under diagnosed and under treated.

### SYMPTOMS

When present, typical symptoms of *Trichomonas vaginalis* are:

#### FEMALE SYMPTOMS APPROXIMATELY 50% ARE ASYMPTOMATIC

Vaginal/vulvar irritation and itching

"Frothy" yellow/green discharge, vaginal odour

Painful urination and/or pain during intercourse

"Strawberry cervix" upon examination

Vaginal pH greater than 5



#### MALE SYMPTOMS APPROXIMATELY 75% ARE ASYMPTOMATIC

Urethral discharge

Itching and painful urination



#### WHAT ARE THE RISK FACTORS<sup>3</sup>?

- Age
- Ethnicity
- Multiple sexual partners
- Past STI infection
- Low education and poverty

#### WHY IS IT UNDER-REPORTED?

- Lack of sensitivity of common diagnostic method
- No formal public health reporting
- Frequently asymptomatic
- Partners often not tested or treated

A photograph of a young man and woman smiling and embracing each other. The man is in the foreground, wearing a light blue button-down shirt, and the woman is behind him, wearing a light blue t-shirt. They are both looking towards the camera.

THERE ARE A NUMBER OF COMPLICATIONS ASSOCIATED WITH A TRICHOMONAS INFECTION, EACH OF WHICH CARRIES SIGNIFICANT HEALTH, SOCIAL AND ECONOMIC COSTS:

A graphic showing the silhouettes of a group of people of various ages standing in a field with tall grass. Overlaid on this are several green rectangular boxes containing text about complications of Trichomonas infection.

**PRETERM LABOR & BIRTH<sup>4</sup>**

**INFERTILITY<sup>8,9</sup>**

**INCREASED RISK OF HIV/HSV<sup>5,6,7</sup>**

**PELVIC INFLAMMATORY DISEASE<sup>10</sup>**

**CERVICAL CANCER<sup>11</sup>**

**PROSTATE CANCER IN MEN<sup>12</sup>**

## DIAGNOSTIC CHALLENGES

There are a number of diagnostic options available. However, choices may have to be made in terms of:



### ACCURACY

Patient receives correct diagnosis



### TIME


Patient receives correct diagnosis in a timely manner



### COST

Diagnosis is obtained cost-effectively and affordably

METHOD	FEATURES
MICROSCOPY	<ul style="list-style-type: none"> <li>The most widely used technique</li> <li>Accuracy varies widely (30-75%)<sup>5</sup>, and is impacted by factors such as subjectivity, training, microscope condition and sample collection/handling</li> <li>Requires observation of live, motile organisms; <i>20% of trichomonads are reported to lose motility within 10 minutes of sample collection</i><sup>5</sup></li> </ul>
CULTURE	<ul style="list-style-type: none"> <li>Long been considered the gold standard</li> <li>Provides greater accuracy than microscopy</li> <li>Labor intensive; can take days for results<sup>3</sup></li> </ul>
MOLECULAR	<ul style="list-style-type: none"> <li>Highly accurate results</li> <li>Expensive in terms of equipment and cost per test; requires specialized training</li> <li>Does not allow for test-and-treat approach</li> </ul>
ANTIGEN OSOM® Trichomonas Rapid Test	<ul style="list-style-type: none"> <li>30 sec. of hands-on time, results in 10 min. or less</li> <li>Accuracy- 95% overall agreement vs. combined reference method (culture and microscopy)</li> <li>No equipment or specialized training required</li> <li>Easy-to-read, objective results</li> <li>Detects antigen; does not require live, motile organisms</li> <li>Patient can collect sample</li> </ul>




## ACCURATE RESULTS WHILE THE PATIENT WAITS — A PATH TO BETTER PATIENT CARE

In a recent independent study, the sensitivity and specificity were 100% and 99.6% for the OSOM® test when compared to culture.

In the same study, when using NAAT as the reference standard, the sensitivity was 95.5%.<sup>13</sup>


The ability of the **OSOM® Trichomonas Rapid Test** to *accurately, quickly and cost effectively* diagnose Trichomonas offers *significant benefits* to the patient and clinician alike:

- Instigate *immediate treatment*
- Provide opportunity for appropriate sexual health education *during the visit*
- Help *prevent further spread* of Trichomonas and *reduce associated health risks*
- *Avoid misuse and over-prescription* of unnecessary antibiotics



# OSOM® Trichomonas Rapid Test Procedure

Visit [www.osomtraining.com](http://www.osomtraining.com) for a multilingual demonstration of procedures.



ORDER	CONFIGURATION	CATALOGUE #
<input type="radio"/> OSOM® TRICHOMONAS RAPID TEST KIT	25 TESTS	181E (CE MARKED)
<input type="radio"/> OSOM® TRICHOMONAS POSITIVE CONTROL KIT	10 SWABS	182 (CE MARKED)
<input type="radio"/> OSOM® VAGINITIS SWAB TRANSPORT SYSTEM	50 SWAB SETS	185

## ONLINE TRAINING

View a simple animation of the test procedure, take a quiz, and print your personalized training certificate online, anytime. To get started, visit **www.osomtraining.com**. Can be used for:

- New operators
- Validating a new test
- Refresher training



## OSOM® CUSTOM CARE

Highly-trained **Technical Service Specialists**, all medical technologists with clinical laboratory backgrounds, are available to assist you with:

- Concerns or questions about any of our products
- Assay use, adoption and staff training
- Record keeping, regulations, and reimbursement
- Evaluation of new methods: remote or onsite assay verification program



## REFERENCES

1. Prevalence and Incidence of Selected Sexually Transmitted Infections, World Health Organization 2011
2. Huppert JS, Batteliger BE, Braslins P, Feldman JA, Hobbs MM, Sankey HZ, Sena AC and Wendel KA. Use of an Immunochromatographic Assay for Rapid Detection of *Trichomonas vaginalis* in Vaginal Specimens. *Journal of Clinical Microbiology*. 2005; 43 (2): 684-687
3. Swygard H, Sena AC, Hobbs MM, Cohen MS: Trichomoniasis: clinical manifestations, diagnosis and management. *Sexually Transmitted Infections* 2004; 91-5
4. Wendel KA. Trichomoniasis: What's New? *Current Infectious Disease Reports* 2003;5:129-34
5. Schwabke, Jane R.: Trichomoniasis care today: A clinician's guide to timely diagnosis and successful treatment, April 2004
6. Chesson, HW, et al: Estimates of the Annual Number and Cost of New HIV Infections Among Women Attributable to Trichomoniasis in the US, *SexTransDiseases*, Vol. 31, No. 9, Sep 2004, 547-551
7. Gottlieb SL, Douglas JM Jr, Foster M, Schmid DS, Newman DR, Baron AE, Bolan G, Iatesta M, Malotte CK, Zenilman J, Fishbein M, Peterman TA, Kamb ML: Project RESPECT Study Group. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. *J Infect Dis*. 2004 Sep 15;190(6):1059-67. Epub 2004 Aug 5
8. Sherman KJ, Daling JR, Weiss NS. Sexually transmitted diseases and tubal infertility. *Sex Transm Dis*. 1987 Jan-Mar;14(1):12-6
9. Grodstein F, Goldman MB, Cramer DW. Relation of tubal infertility to history of sexually transmitted diseases. *Am J Epidemiol*. 1993 Mar 1; 137(5):577-84
10. Moodley P, Wilkinson D, Connolly C, Moodley J, Sturm AW. *Trichomonas vaginalis* is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. *Clin Infect Dis*. 2002 Feb 15;34(4):519-22. Epub 2002 Jan 7
11. Gram IT, Macaluso M, Churchill J, Stalsberg H. *Trichomonas vaginalis* (TV) and human papillomavirus (HPV) infection and the incidence of cervical intraepithelial neoplasia (CIN) grade III. *Cancer Causes Control*. 1992 May;3(3):231-6
12. Stark, Jennifer R., et al. *Prospective Study of Trichomonas Vaginalis Infection and Prostate Cancer Incidence and Mortality: Physicians' Health Study*. *J Natl Cancer Inst* 101.20 (2009): 1406-411
13. Nathan B, Heron D, Applah J, Saunders P, Bru, R, Nichols T, Alexander S, Baraister P, Ison C: Evaluation of NAAT and POCT for detecting *T. vaginalis*



**Distributed in the UK by:**

Alere Ltd,  
Pepper Road, Hazel Grove, Stockport, SK7 5BW  
0161 483 5884 | ukcustomer@alere.com | [alere.co.uk](http://alere.co.uk)